Therapeutic anti-NLGP monoclonal antibody for carcinoembryonic antigen expressing tumors is nontoxic to Swiss and BALB/c mice.

摘要: A murine monoclonal antibody (mAb), 1C8 was developed against a novel glycoprotein NLGP and its unique property to recognize carcinoembryonic antigen (CEA) reported. Utilizing this CEA recognizing property, is successful restrict the growth of CEA(+) human cancers both in vitro vivo. Here, we have thoroughly evaluated toxicity profile mAb on different physiological systems tumor-free tumor-bearing Swiss BALB/c mice. Effective concentration (25 μg/mice) caused no behavioral changes animals death recorded. Moreover, little increase body organ weights all mice groups noted. MAb showed adverse effect hematological system, but hematostimulation noticed, as evidenced by increased hemoglobin content, leukocyte count lymphocyte numbers. Liver enzymes like alkaline phosphatase, SGOT, SGPT nephrological products urea creatinine assessment confirmed abnormalities hepatic renal functions. Number T cells, B NK macrophages dendritic cells upregulated vivo treatment with significant downregulation regulatory cells. During serum levels type 1 cytokines were over 2 cytokines. This also did not induce any titer following treatment. Accumulated evidences from strongly suggest that completely safe, thus, can be recommended for further clinical trial therapy tumors.